SCHEDULE: Armistice Capital Discloses 8.79% Stake in Rani Therapeutics

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.79% in Rani Therapeutics Holdings-A, totaling 4,312,354 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed a Schedule 13G.
• The filing discloses their beneficial ownership of 4,312,354 shares of Common Stock in Rani Therapeutics Holdings-A.
• This ownership represents 8.79% of the class of securities.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership, not an operational or financial performance report, thus it carries a neutral sentiment regarding company performance.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (8.79%) by Armistice Capital and Steven Boyd could be viewed positively by other shareholders, indicating institutional confidence or interest in Rani Therapeutics. It also identifies a major shareholder whose actions could influence future stock performance.

Key Dates

Keywords

Rani Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Investment Management